Clin2
NCT04411225Possibly a fitRecruiting

CBD may help early psychosis along with usual treatment

Early Psychosis

Treatments studied

Part of Mental health clinical trials.

This Phase 3 trial tests whether taking cannabidiol (CBD) can reduce symptoms when added to standard care for early psychosis (like first-episode psychosis or attenuated psychosis). It may help some people have fewer troubling thoughts or perceptions over time.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
120 people
Ages
16 years to 30 years
Study type
Interventional

Who can take part

  • Your psychosis symptoms started within the last 2 years (first episode) or you have attenuated psychosis syndrome (APS)
  • You have been stable on the same treatment plan for at least 8 weeks (no major change in medications/doses recently)
  • Your current symptoms are not too severe right now (only up to mild-to-moderate “positive” symptoms)
  • Your depression symptoms are low based on a schizophrenia depression rating scale
  • You must not have certain medical/neurologic conditions, major head injury, or high suicide risk

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06740383Recruiting
Study of early psychosis and treatments

This study looks at people who have had psychosis for less than 4 years to understand how their symptoms change over time and how they respond to treatment. By using brain scans and other tests, researchers hope to find better ways to personalize care for early psychosis.

Hartford, Connecticut
NCT06778564Not yet recruiting· Phase 3
CBD (cannabidiol) for early psychosis

This study tests if adding a CBD medication to your current antipsychotic can improve symptoms in people with schizophrenia or related disorders who started treatment recently but aren't fully better yet.

Vienna
NCT07326124Not yet recruiting· Phase 3
Testing cannabidiol for early psychosis

This trial tests whether adding cannabidiol (CBD) to clozapine improves symptoms in people with early psychosis. It is for those who have been on clozapine for at least 8 weeks and still have some symptoms.

Berlin
NCT07434973Not yet recruiting· Phase 3
Early psychosis prevention with cannabidiol (CBD)

This trial tests if cannabidiol (a non-psychoactive cannabis component) can prevent psychosis in people ages 12-35 at high risk. It compares CBD to a placebo to see if it reduces symptoms and delays or prevents a first psychotic episode.

Vienna
NCT05457465Recruiting· Phase 2
Cannabidiol study for anxiety and depression in bipolar disorder

This Phase 2 study tests whether cannabidiol (CBD) can reduce anxiety and depressive symptoms in people with bipolar disorder. It may help if your mood symptoms are persistent and you’re already on stable bipolar medications.

Belmont, Massachusetts
NCT07245212Not yet recruiting
Cannabis Clinic for People With Early Psychosis

This trial tests a specialized cannabis clinic designed to help people cut back or stop using cannabis if they've had a first episode of psychosis. The goal is to see if the clinic helps reduce cannabis use and improve mental health.

London

Hear when a new Early Psychosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.